Rep. David Taylor Unloads Amgen Inc. (NASDAQ:AMGN) Shares

Posted by Chris Copeland on Sep 8th, 2026

Representative David Taylor (Republican-Ohio) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on September 05th, the Representative disclosed that they had sold between $1,001 and $15,000 in Amgen stock on August 26th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SCHWAB JOINT BROKERAGE #1 (HOME GROWN)” account.

Representative David Taylor also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Vertex Pharmaceuticals (NASDAQ:VRTX) on 8/26/2026.
Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of Fifth Third Bancorp (NASDAQ:FITB) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of American Electric Power (NASDAQ:AEP) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 8/14/2026.
Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/11/2026.
Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 8/11/2026.
Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 8/11/2026.
Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 7/24/2026.

Amgen Stock Performance

AMGN opened at $437.23 on Tuesday. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm has a market cap of $236.38 billion, a PE ratio of 27.17, a P/E/G ratio of 3.15 and a beta of 0.43. The business has a fifty day simple moving average of $398.92 and a 200-day simple moving average of $367.59. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $447.03.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating the consensus estimate of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.Amgen’s revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the business posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities analysts predict that Amgen Inc. will post 22.97 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio is 62.65%.

Insider Activity at Amgen

In related news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. The trade was a 16.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Nancy Grygiel sold 2,970 shares of Amgen stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 6,222 shares of company stock worth $2,540,926 over the last three months. 0.85% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on AMGN. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Truist Financial boosted their target price on shares of Amgen from $340.00 to $362.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. UBS Group boosted their target price on Amgen from $420.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Robert W. Baird lifted their price objective on Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. Finally, Barclays upped their target price on shares of Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fourteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $381.68.

Check Out Our Latest Stock Analysis on AMGN

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Amgen’s olpasiran remains a potentially significant opportunity in the Lp(a)-lowering market. The Novartis result does not determine olpasiran’s outcome, leaving room for Amgen to differentiate its drug if its late-stage trial demonstrates a reduction in cardiovascular events. Cholesterol drug setback casts doubt over multibillion-dollar race
Neutral Sentiment: The disappointing Novartis data is affecting several companies pursuing Lp(a) therapies, including Amgen and Eli Lilly, reflecting broader investor caution toward experimental drug pipelines rather than a change to Amgen’s current operating results. Why Amgen Stock Is Dropping After Swiss Rival’s Trial Setback
Negative Sentiment: Novartis’ pelacarsen failed to reduce cardiovascular events despite lowering harmful Lp(a) cholesterol. Investors now face greater uncertainty over whether Amgen’s olpasiran can validate the same biological mechanism in its approximately 7,297-patient heart-outcomes study. Amgen’s 7,297-Patient Heart Bet Just Inherited a Higher Bar
Negative Sentiment: The trial failure has already prompted investor concern about olpasiran’s phase 3 prospects, making the drug a higher-risk pipeline asset and contributing to the recent pullback in AMGN. Amgen Shares Fall as Novartis’ Pelacarsen Misses Phase III Study Goal

Hedge Funds Weigh In On Amgen

Several hedge funds and other institutional investors have recently modified their holdings of AMGN. Brighton Jones LLC increased its holdings in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC lifted its position in Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after buying an additional 114 shares in the last quarter. Schnieders Capital Management LLC. grew its holdings in Amgen by 29.3% during the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after acquiring an additional 5,853 shares during the last quarter. Main Street Financial Solutions LLC increased its position in Amgen by 11.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock valued at $1,141,000 after acquiring an additional 416 shares in the last quarter. Finally, Ieq Capital LLC raised its stake in shares of Amgen by 5.1% in the second quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock worth $15,120,000 after acquiring an additional 2,611 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Amgen Company Profile

(Get Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.